DNA methylation is a key mechanism for transcriptional regulation, and dramatic changes in DNA methylation of regulatory regions occur during normal development and in pathological conditions 1,2 . Individual deletion of the DNA methyltransferases (Dnmt1, Dnmt3a and Dnmt3b) in mice leads to embryonic or postnatal lethality 3, 4 . Proper development also requires active and passive DNA demethylation 5 . The three mammalian TET proteins (TET1, TET2 and TET3) catalyze the oxidation of 5mC to 5hmC, which can serve as an intermediate in active DNA demethylation 6-8 . Loss of TET proteins leads to hypermethylation of the promoters and enhancers of developmental genes in mouse embryos and mouse embryonic stem cells (mESCs) 7, [9] [10] [11] . Although TET gene inactivation clearly impairs embryonic development and cellular differentiation, it is difficult to establish direct causal relationships between TETmediated DNA demethylation, transcriptional output, and developmental or pathological phenotypes owing to the general challenge of distinguishing global versus locus-specific effects for epigenetic regulators 12-14 .
DNA methylation is a key mechanism for transcriptional regulation, and dramatic changes in DNA methylation of regulatory regions occur during normal development and in pathological conditions 1, 2 . Individual deletion of the DNA methyltransferases (Dnmt1, Dnmt3a and Dnmt3b) in mice leads to embryonic or postnatal lethality 3, 4 . Proper development also requires active and passive DNA demethylation 5 . The three mammalian TET proteins (TET1, TET2 and TET3) catalyze the oxidation of 5mC to 5hmC, which can serve as an intermediate in active DNA demethylation [6] [7] [8] . Loss of TET proteins leads to hypermethylation of the promoters and enhancers of developmental genes in mouse embryos and mouse embryonic stem cells (mESCs) 7, [9] [10] [11] . Although TET gene inactivation clearly impairs embryonic development and cellular differentiation, it is difficult to establish direct causal relationships between TETmediated DNA demethylation, transcriptional output, and developmental or pathological phenotypes owing to the general challenge of distinguishing global versus locus-specific effects for epigenetic regulators [12] [13] [14] .
To link transcriptional outcomes to TET-mediated demethylation, previous studies have focused on TET actions at enhancers and found examples in which loss of the TET proteins caused hypermethylation and decreased gene expression 11, 15 . However, the consequences of TET activities at promoters remain ambiguous. In particular, bivalent promoters, which have H3K4me3 and H3K27me3 histone marks on the same or adjacent nucleosomes, are hypomethylated like active promoters. Yet, unlike active promoters, which support productive transcription, bivalent promoters are associated with negligible transcription, similar to silent promoters that have high levels of DNA methylation [16] [17] [18] [19] . Thus, at bivalent promoters, the importance of DNA methylation for gene expression regulation is not readily apparent.
hESCs reflect a later developmental stage than mESCs. Here we have generated viable hESC lines with mutations in all three TET genes (TKO hESCs). Although hESCs have greater global CpG methylation than mESCs 20 , inactivating the TET genes still produces hypermethylation in a locus-specific manner. This hypermethylation is observed among enhancers and other regulatory regions, and is particularly prominent at bivalent promoters. In the absence of the TET proteins, the de novo methyltransferase DNMT3B causes aberrant hypermethylation at bivalent promoters, which leads to impaired gene activation upon differentiation. Thus, the TET proteins are necessary to maintain hypomethylation at bivalent promoters, which is critical for proper cellular differentiation during early human development.
Results
Bivalent promoter hypermethylation in TKO hESCs. Because all three TET genes were expressed in hESCs ( Supplementary Fig. 1a) TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells Nipun Verma 1,2 , Heng Pan 3,4 , Louis C. Doré 5 , Abhijit Shukla 1 , Qing V. Li 1,6 , Bobbie Pelham-Webb 2 , Virginia Teijeiro 1,4 , Federico González 1,9 , Andrei Krivtsov 7 , Chan-Jung Chang 8 , Eirini P. Papapetrou 8 , Chuan He 5 , Olivier Elemento 3 * and Danwei Huangfu 1 * TET enzymes oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which can lead to DNA demethylation. However, direct connections between TET-mediated DNA demethylation and transcriptional output are difficult to establish owing to challenges in distinguishing global versus locus-specific effects. Here we show that TET1, TET2 and TET3 triple-knockout (TKO) human embryonic stem cells (hESCs) exhibit prominent bivalent promoter hypermethylation without an overall corresponding decrease in gene expression in the undifferentiated state. Focusing on the bivalent PAX6 locus, we find that increased DNMT3B binding is associated with promoter hypermethylation, which precipitates a neural differentiation defect and failure of PAX6 induction during differentiation. dCas9-mediated locus-specific demethylation and global inactivation of DNMT3B in TKO hESCs partially reverses the hypermethylation at the PAX6 promoter and improves differentiation to neuroectoderm. Taking these findings together with further genome-wide methylation and TET1 and DNMT3B ChIP-seq analyses, we conclude that TET proteins safeguard bivalent promoters from de novo methylation to ensure robust lineage-specific transcription upon differentiation.
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and none had been genetically deleted previously, we used the iCRISPR platform developed in our laboratory 21 to generate a panel of TET1-, TET2-and TET3-knockout lines in the HUES8 and MEL-1 hESC backgrounds ( Fig. 1a and Supplementary Tables 1 and 2) . hESCs in which all three TET genes were inactivated (TKO hESCs) had no detectable 5hmC signal by mass spectrometry or 5hmC dot blot ( Fig. 1b and Supplementary Fig. 1b ,c) but showed no difference in morphology, self-renewal capacity or pluripotency marker expression when compared to wild-type (WT) hESCs (Fig. 1c,d and Supplementary Fig. 1d ). However, TKO hESCs showed a complete inability to form teratomas and impaired induction of key early differentiation genes upon spontaneous embryoid body differentiation ( Fig. 1e,f ), suggesting that the TET proteins may be particularly important for the regulation of cellular differentiation.
Loss of the TET genes resulted in locus-specific hypermethylation rather than a global gain of methylation. Mass spectrometry analysis did not show a difference in 5mC levels between TKO and WT hESCs ( Fig. 1b and Supplementary Fig. 1c ), similar to previous findings in mESCs 11 . Instead, whole-genome bisulfite sequencing (WGBS) of WT and TKO HUES8 hESCs identified 3,523 hypermethylated differentially methylated regions (hyper-DMRs) each with at least five hypermethylated CpGs and a ≥10% methylation 
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difference when comparing TKO to WT hESCs (Supplementary Data 1). Using the same criterion, we also observed 3,832 hypomethylated differentially methylated regions (hypo-DMRs) ( Fig. 2a ). These hypo-DMRs primarily occurred at CpGs outside of CpG islands (CGIs) (Fig. 2b) . They could be a direct result of TET gene inactivation or a secondary effect, possibly due to redirection of the DNMT proteins to novel sites in TKO hESCs. Notably, CGIs were enriched in regulatory regions and showed increased (Hypo) in methylation between TKO and WT HUES8 hESCs by WGBS. e, Heat map of the average 5mC level differences between TKO and WT HUES8 hESCs by WGBS with respect to the center of regions with annotated histone modifications. f, DNA methylation differences between TKO and WT HUES8 hESCs by ERRBS at different promoter types. Box-and-whisker plots were generated using the methylation difference at individual promoters. The error bars show the 10-90% confidence interval. The lower and upper limits of the box represent the first and third quartile, respectively, and the bar at the center of the box indicates the median. The promoters are divided into four groups on the basis of histone modification patterns. The details of promoter definitions can be found in the Methods; n = 2 independent experiments. Statistical analysis was performed using one-way ANOVA: ****P < 0.0001. g, Representation of active, initiated, bivalent and silent promoters among promoters showing different degrees of methylation change between TKO and WT HUES8 hESCs by ERRBS; n indicates the total number of promoters in each DNA methylation change group for n = 2 independent experiments. h, Overlap of bivalent promoters showing greater than 5% methylation increase in HUES8 and MEL-1 TKO lines as compared to corresponding HUES8 and MEL-1 WT lines by ERRBS. The P value for the overlap of hypermethylation at bivalent promoters is given (Fisher's exact test). WGBS, n = 1 independent experiment; ERRBS, n = 2 independent experiments (2 independent experiments for WT and TKO HUES8 cells, 2 independent experiments for WT and TKO MEL-1 cells).
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NATurE GENETICS methylation in TKO hESCs ( Fig. 2b ). Furthermore, hyper-DMRs were enriched for regulatory regions such as promoters and enhancers ( Fig. 2c ). In comparison to other promoter types, bivalent promoters had the greatest magnitude of methylation increase (Fig. 2b) , and a relatively high proportion of bivalent promoters gained methylation ( Fig. 2d ), as exemplified by the HOXA7 and HOXA9 loci 21 ( Supplementary Fig. 1e and Supplementary Data 2). Indeed, significant gain of methylation in TKO hESCs was found to center around genomic sites with both H3K4me3 and H3K27me3 marks ( Fig. 2e ). Finally, we performed genome-wide 5hmC profiling through 5hmC-Seal 22 and found that DNA hypermethylation in TKO hESCs was detected most strongly in regions that had 5hmC peaks in WT hESCs ( Fig. 2e ), supporting our hypothesis that loss of the TET proteins is directly responsible for gain of methylation. Gene Ontology (GO) analysis showed that hypermethylated bivalent promoters in particular, but also hypermethylated poised enhancers (marked by H3K4me1 but not H3K27ac), were associated with developmental categories, suggesting that the methylation aberrations could be responsible for the differentiation defects of TKO hESCs ( Supplementary Fig. 2a ).
To further investigate the methylation changes at bivalent promoters, we performed enhanced reduced-representation bisulfite sequencing (ERRBS), which focuses on CGIs and thus increases sequencing coverage of promoter regions 23 . By ERRBS, we observed similar methylation changes in the MEL-1 TKO line as in the HUES8 TKO line. ERRBS analysis showed ~12,000 hyper-DMRs and an insignificant number of hypo-DMRs in TKO lines as compared to WT hESCs ( Fig. 2a and Supplementary Data 3 and 4). We further analyzed the methylation changes according to promoter types: bivalent promoters (marked by H3K4me3 and H3K27me3), active promoters (marked by H3K4me3 and H3K79me2), initiated promoters (marked by H3K4me3 only) and silent promoters (based on the absence of H3K4me3) 24 . Overall, about half of bivalent promoters showed hypermethylation by ERRBS and WGBS analyses ( Fig. 2d and Supplementary Fig. 2b ). Although WGBS also showed that a fraction of promoters became hypomethylated after TET gene inactivation, this was not observed by ERRBS. The hypomethylation detected by WGBS is likely due to hypomethylation of non-CGI CpGs that are frequently found within or near promoter regions.
In comparison to other promoter types, bivalent and silent promoters showed a greater magnitude of methylation increase in HUES8 and MEL-1 TKO lines ( Fig. 2f and Supplementary Fig. 2c ). Notably, we observed increasing fractions of bivalent promoters among promoters with greater methylation changes ( Fig. 2g and Supplementary Fig. 2d ). Although bivalent promoters composed 27% of all promoters evaluated by ERRBS, they constituted 60-74% of all promoters with a >60% increase in DNA methylation. We observed similar results in HUES8 and MEL-1 TKO hESCs, with 1,326 and 1,579 bivalent promoters gaining methylation, respectively (Supplementary Data 5 and 6). Individual bivalent promoters showed similar methylation changes in these two lines ( Supplementary Fig. 2e ), and 87% of the 1,326 hypermethylated bivalent promoters in HUES8 TKO hESCs also gained methylation in MEL-1 TKO hESCs ( Fig. 2h ). Overall, these results indicate that the TET proteins are critical to preserve hypomethylation at bivalent promoters and, in their absence, a reproducible subset of bivalent promoters becomes aberrantly hypermethylated.
We also compared our data with previous TKO mESC data 11 . Of the 732 bivalent promoters that became hypermethylated ( >20% increase) in TKO mESCs, 517 were also bivalent in hESCs, of which 289 (~56%) were associated with hyper-DMRs in TKO hESCs. The remaining 215 promoters were not bivalent in hESCs, and only 55 (~25.6%) were associated with hyper-DMRs in TKO hESCs ( Supplementary Fig. 2f ). Thus, bivalent promoters found in both mESCs and hESCs tend to show similar methylation changes after TET gene inactivation.
Hypermethylation of the PAX6 promoter. TKO hESCs showed relatively few transcriptional changes in comparison to WT cells ( Supplementary Fig. 3a ). We found that hypermethylation of active, initiated and silent promoters was associated with a decrease in gene expression. In contrast, genes associated with hypermethylated bivalent promoters and poised enhancers did not show an overall change in expression in TKO hESCs ( Supplementary Fig. 3b ). 5mC MassARRAY EpiTYPER analysis confirmed that the bivalent promoters of selected developmental genes (FOXA2, GATA2, PAX6, SOX10 and SOX17) showed significant hypermethylation in TKO hESCs, whereas the active promoters for housekeeping and pluripotency genes did not ( Supplementary Fig. 3c ). Hypermethylation of the LEFTY2 enhancer (an active enhancer marked by H3K4me1 and H3K27ac) in TKO hESCs was associated with a significant decrease in gene expression, as has previously been described in TKO mouse embryos 10 ( Supplementary Fig. 3c,d ), whereas no expression change was detected for housekeeping and pluripotency genes. Notably, hypermethylation of the bivalent promoters was not associated with a consistent decrease in gene expression. For instance, no change in PAX6 expression was observed. A few genes associated with bivalent promoters showed up-or downregulation, but expression levels were generally low (Supplementary Fig. 3d and Supplementary Data 7) .
We were intrigued that, despite promoter hypermethylation, genes with bivalent promoters such as PAX6 did not show a change in expression at the hESC stage ( Supplementary Fig. 3d ). Noticing that PAX6 (as well as FOXA2 and SOX10) failed to be upregulated upon spontaneous embryoid body differentiation ( Fig. 1f ), we speculated that the hypermethylation at bivalent promoters could affect activation of gene expression following exposure to differentiation signals. We chose to focus on PAX6 because it is a critical gene for human neural development and is highly expressed during in vitro differentiation of hESCs into the neural lineage [25] [26] [27] , thus allowing us to use neural differentiation to track the effects of TET gene deletion on PAX6 expression as well as cellular differentiation. PAX6 has wellannotated promoters and enhancers ( Fig. 3a and Supplementary  Fig. 4a ) [28] [29] [30] [31] [32] . 5mC MassARRAY analysis of these regions revealed that only the bivalent P0 promoter of PAX6 showed hypermethylation in TKO HUES8 hESCs ( Fig. 3b and Supplementary Fig. 4b ), which was recapitulated in the MEL-1 TKO line ( Supplementary Fig. 4c ). We further generated two 'TKO-repaired' lines, TKO-r1 and TKO-r2, through CRISPR-Cas9-mediated homology-directed repair (HDR) for comparison with isogenic WT and TKO hESC lines to rule out the possibility of CRISPR off-target effects ( Fig. 3c ). TKO hESCs that underwent the HDR targeting but retained the original biallelic TET1 mutations, TKO-nr, were used as passage-matched controls. Repair of one TET1 allele to the WT sequence in TKO hESCs was sufficient to restore 5hmC to near WT levels as assessed by mass spectrometry (Fig. 3d ), and it also reversed PAX6 P0 promoter hypermethylation (Fig. 3b) . Notably, the TKO-repaired line was able to form teratomas, indicating a rescue in differentiation capacity ( Fig. 1e ).
To confirm that hypermethylation of the PAX6 P0 promoter is a direct consequence of losing the TET proteins, we performed 5hmC analysis using the Epimark 5hmC Analysis kit 33 and genomewide hMe-Seal 22 . Both methods showed 5hmC enrichment at the PAX6 P0 promoter in WT hESCs ( Fig. 3e ,f). We also detected TET1 binding at the PAX6 P0 promoter in WT hESCs by ChIPseq and ChIP-qPCR ( Fig. 3f,g) . Approximately 51% of 5hmC peaks at promoters and 75% of 5hmC peaks globally overlapped with TET1 peaks ( Supplementary Fig. 4d,e ). Incomplete overlap between 5hmC and TET1 peaks could be due to 5hmC production by TET2 or TET3. Globally, TET1 bound to bivalent, active and initiated promoters at the transcription start site (TSS). Binding of TET1 overlapped with 5hmC signals, which extended into the promoter and gene body ( Fig. 3h and Supplementary Fig. 4f ). 
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The functional relevance of TET binding and 5hmC signal is supported by a greater methylation increase in TKO hESCs at bivalent promoters that had 5hmC peaks than at bivalent promoters that did not have 5hmC peaks ( Fig. 3i and Supplementary Fig. 4g ). Overall, ~92% and ~50% of hyper-DMRs at bivalent promoters overlapped with 5hmC and TET1 peaks, respectively ( Supplementary Fig. 4h ). The greater overlap between hyper-DMRs and 5hmC peaks is likely due to production of 5hmC by TET2 and TET3. Altogether, these findings support the conclusion that TET1 binding at bivalent promoters (such as the PAX6 P0 promoter) leads to 5hmC production while TET inactivation causes 5hmC depletion and aberrant promoter hypermethylation.
Impaired neural differentiation of TKO hESCs. Because PAX6 is expressed in early neuroectoderm derived from hESCs 26, 27 and has been shown to be both necessary and sufficient for neuroectoderm formation from hESCs 25 , we speculate that hypermethylation of the PAX6 P0 promoter in TKO hESCs may impede hESC differentiation into the neural lineage, as suggested by the embryoid body differentiation results (Fig. 1f ).
We performed neuroectoderm differentiation using the dual-SMAD-inhibition protocol 34 ( Fig. 4a and Supplementary Fig. 5a ). In contrast to HUES8 WT and TKO-repaired hESCs, HUES8 TKO hESCs formed significantly fewer PAX6 + neuroectoderm cells at each point during differentiation ( Fig. 4b-d ), suggesting a defect in the acquisition rather than the maintenance of the neuroectoderm fate. Notably, in differentiation of HUES8 TKO hESCs, ~40% of cells remained positive for OCT4 (also known as POU5F1) after 10 d of differentiation, as shown by immunostaining and FACS analysis ( Fig. 4c,e ). Analysis of additional markers as well as the MEL-1 TKO line confirmed the neuroectoderm differentiation defect of TKO hESCs ( Fig. 4f and Supplementary Fig. 5b-d) . Notably, comparison of the HUES8 TKO line to HUES8 hESCs with individual and double knockout of TET genes showed that the severity of the neuroectoderm differentiation defect depended on TET gene dosage. Loss of TET1 had the largest effect on bulk 5hmC levels ( Fig. 1b ) as well as neuroectoderm differentiation, as determined by FACS, immunostaining, and RT-qPCR analysis for PAX6 and SOX1 expression ( Supplementary Fig. 6a -c).
Promoter hypermethylation hinders PAX6 expression upon differentiation. PAX6 is expressed at a very low level in hESCs, and hypermethylation of the P0 promoter in TKO hESCs had no effect on PAX6 gene expression ( Supplementary Fig. 3d ). We hypothesized that hypermethylation of the PAX6 P0 promoter prevents activation of PAX6 expression upon differentiation and leads to the neuroectoderm differentiation defect in TKO hESCs. Supporting this hypothesis, 5mC MassARRAY analysis showed aberrant hypermethylation at the PAX6 P0 promoter in TKO hESCs both before and during neuroectoderm differentiation (Fig. 3b ). To establish direct causality, we needed to determine whether loss of PAX6 expression accounts for the neuroectoderm differentiation defect of TKO hESCs and then investigate whether hypermethylation of the P0 promoter is responsible for the loss of PAX6 expression. We first performed a rescue experiment in which we expressed the PAX6 transgene under the control of a doxycycline-inducible promoter in TKO cells during neuroectoderm differentiation ( Fig. 5a ). TKO cells exposed to doxycycline were able to upregulate the neuroectoderm markers SOX1 and FOXG1 and downregulate the pluripotency markers POU5F1 and NANOG (Fig. 5b,c and Supplementary  Fig. 7a ). However, expression of SOX10 and endogenous PAX6 was not restored ( Supplementary Fig. 7a ). In comparison to the promoters of SOX1 and FOXG1, the SOX10 and PAX6 promoters showed a much greater methylation increase in TKO hESCs (Supplementary Data 5), which may prevent their expression even when the PAX6 transgene is overexpressed.
The above findings suggest that failure of PAX6 induction is largely responsible for the impaired neuroectoderm differentiation observed in TKO hESCs. The failure of PAX6 induction could be due to hypermethylation of the PAX6 P0 promoter. Alternatively, it could result from other causes, such as the failure to induce upstream transcription factors that activate PAX6 expression or perhaps a failure in exiting the pluripotency network. Thus, we investigated whether reversing hypermethylation specifically at the PAX6 P0 promoter could rescue PAX6 induction during neuroectoderm differentiation. We developed a targeted demethylation strategy by first fusing the TET1 catalytic domain (TET1CD) to a nuclease-'dead' Cas9 (dCas9; Supplementary Fig. 7b ). With the appropriate guide RNAs (gRNAs), this dCas9-TET1CD fusion protein can be recruited to specific genomic sites where the TET1 catalytic domain can then oxidize 5mC to 5hmC and induce DNA demethylation, as shown in recent studies using similar strategies [35] [36] [37] [38] . We transiently transfected three individual CRISPR gRNAs targeting the PAX6 P0 promoter region with TET1 enrichment and a 5hmC peak in WT hESCs ( Supplementary Fig. 7c ). All three gRNAs-Cr6, Cr7 and Cr9-caused a significant decrease in methylation by MassARRAY analysis at the PAX6 P0 promoter in TKO hESCs as compared to non-transfected controls ( Supplementary Fig. 7d ).
To enable persistent demethylation, we used a lentiviral vector to constitutively express the Cr6, Cr7 and Cr9 gRNAs in TKO hESCs with doxycycline-inducible expression of the dCas9-TET1CD fusion protein. A number of controls were performed, including a no-doxycycline control, a nontargeting gRNA control and a control with mutated dCas9-TET1CD fusion protein (dCas9-TET1CD/Mut), in which the TET1 catalytic domain was inactivated by targeted mutagenesis ( Supplementary Fig. 7b ). After 10 d of doxycycline treatment, we performed 5mC MassARRAY analysis at the PAX6 P0 promoter ( Fig. 5a ) and observed greater demethylation in TKO hESCs that expressed both dCas9-TET1CD and the three PAX6 P0 gRNAs than in the controls ( Fig. 5d and Supplementary Fig. 7e ). Neuroectoderm differentiation was then performed without further doxycycline treatment. dCas9-TET1CD TKO hESCs expressing PAX6 P0 gRNAs and treated with doxycycline before neuroectoderm differentiation showed upregulation of PAX6 expression after the initiation of neuroectoderm differentiation, whereas the controls did not (Fig. 5e,f and Supplementary Fig. 7e ). Thus, the hypermethylation of the PAX6 promoter observed in undifferentiated TKO hESCs is directly responsible for the failure of PAX6 induction following neuroectoderm differentiation.
We further tested dCas9-TET1CD-mediated targeted demethylation on the hypermethylated bivalent promoter of SOX10 and the hypermethylated enhancer of LEFTY2 in TKO hESCs. We found that targeted demethylation of the hypermethylated LEFTY2 enhancer was able to increase expression of LEFTY2 in TKO hESCs. In contrast, targeted demethylation of the hypermethylated SOX10 bivalent promoter had no effect on SOX10 expression at the hESC stage but increased SOX10 expression after differentiation, as seen with PAX6 ( Supplementary Fig. 7e ). These results support the conclusion that hypermethylation of a bivalent promoter impairs gene expression upon differentiation. Although targeted demethylation resulted in a significant increase in gene expression that is comparable to previous reports [35] [36] [37] [38] , expression did not reach WT levels. This may be due to incomplete demethylation. Additional chromatin changes at the target locus or elsewhere in TKO hESCs could also affect expression of the target gene directly or indirectly.
De novo methylation causes PAX6 promoter hypermethylation. The DNA methyltransferases-DNMT1, DNMT3A and DNMT3B-are responsible for cytosine methylation. We speculated that hypermethylation of the PAX6 P0 promoter and the resulting neuroectoderm differentiation defect could be due to The color key for percent methylation is shown to the right of the heat map. Methylation analysis at the PAX6 P0 promoter was performed for these cell lines with and without doxycycline (Dox) treatment; n = 3 independent experiments. Statistical analysis was performed by Student's t test (two-sided): ****P < 0.0001. e, qPCR of PAX6 expression on day 10 of neuroectoderm differentiation for TKO hESCs expressing PAX6-targeting gRNAs with either the dCas9-TET1CD/ Mut or dCas9-TET1CD fusion protein. PAX6 expression was analyzed for these cell lines with and without doxycycline treatment before differentiation; n = 3 independent experiments. Data are presented as means ± s.d. Statistical analysis was performed by Student's t test (two-sided): ***P < 0.001. f, Immunofluorescence of PAX6 on day 10 of neuroectoderm differentiation for TKO hESCs expressing PAX6-targeting gRNAs with either the dCas9-TET1CD/Mut or dCas9-TET1CD fusion protein. TKO hESCs expressing the dCas9-TET1CD fusion and a nontargeting gRNA were also used as a control. PAX6 immunofluorescence was analyzed for these cell lines with and without doxycycline treatment before differentiation. Scale bar, 100 μm.
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increased expression or activity of the DNMTs in TKO hESCs. There were no differences in expression of the DNMT genes between WT and TKO hESCs ( Supplementary Fig. 8a) ; however, ChIP-qPCR analysis showed increased binding of DNMT3B, but not DNMT1 or DNMT3A, at the PAX6 P0 promoter in TKO hESCs as compared to WT hESCs ( Fig. 6a and Supplementary Fig. 8b) . Thus, we further investigated whether DNMT3B is responsible for the hypermethylation at the PAX6 P0 promoter in TKO hESCs through genetic deletion. By applying a CRISPR gRNA that targets the sequence corresponding to the cytosine C5 methyltransferase domain of DNMT3B in TKO hESCs, we generated a TET1, TET2, TET3 and DNMT3B quadruple-knockout (QKO) line. QKO hESCs had a ~35% reduction in methylation at the PAX6 P0 promoter as compared to passage-matched TKO hESCs (Fig. 6b ). Furthermore, there was partial rescue of the neuroectoderm differentiation phenotype as compared to TKO hESCs: QKO cells formed PAX6 and SOX1 double-positive cells (Fig. 6c ), and few cells remained OCT4 + after 10 d of neuroectoderm differentiation. RT-qPCR analysis also showed rescue of expression for neuroectoderm markers PAX6 and SOX1 and proper downregulation of pluripotency markers POU5F1 and NANOG (Fig. 6d ). Our results suggest that DNMT3B activity at the PAX6 P0 promoter is responsible for the hypermethylation and neuroectoderm differentiation phenotypes observed in TKO hESCs. In WT hESCs, TET proteins or resulting 5hmC marks may 
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actively block de novo methylation by DNMT3B to maintain a hypomethylated PAX6 P0 promoter and enable neuroectoderm differentiation ( Fig. 7) . We performed ERRBS for passage-matched WT, TKO and QKO lines to investigate whether our findings at the PAX6 P0 promoter apply to other bivalent promoters. We found that QKO hESCs showed a global decrease in methylation, both within and outside of CGIs, and in all promoter types. Bivalent promoters showed a larger decrease in methylation between QKO and TKO hESCs than active and initiated promoter types, but less of a decrease than silent promoters (Fig. 8a,b, Supplementary Fig. 8c,d and Supplementary  Data 8 ). Furthermore, bivalent promoters, in comparison to nonbivalent promoters, had greater overlap with hyper-DMRs that were present after TET gene inactivation as well as higher overlap with hypo-DMRs that were present after DNMT3B inactivation in the TKO background ( Fig. 8c and Supplementary Fig. 8e ). This suggests that the TET and DNMT proteins dynamically regulate the methylation state of bivalent promoters. Approximately 90% of the bivalent promoters that lost methylation in QKO hESCs had previously gained methylation in TKO hESCs (in comparison to WT hESCs). Conversely, ~57% of the bivalent promoters that gained methylation after TET gene inactivation lost methylation after DNMT3B was mutated (Fig. 8d ). Thus, at many bivalent promoters, continuous DNMT3B activity is needed for the hypermethylation phenotype in TKO hESCs.
Our results thus far indicate that DNMT3B is responsible for the majority of the bivalent promoter hypermethylation that occurs after TET gene inactivation. We performed DNMT3B ChIP-seq to investigate whether bivalent promoters are directly targeted by DNMT3B. DNMT3B showed relatively insignificant overall binding to promoter regions ( Supplementary Fig. 8e ) in WT and TKO hESCs, similar to previous results of DNMT3B ChIP-seq in WT mESCs 39 . This may be due to weak DNMT3B binding or technical difficulties in DNMT3B ChIP. Nevertheless, among the promoters with DNMT3B peaks in TKO hESCs, 74% of the 293 bivalent promoters and 21% of the 1,017 non-bivalent promoters gained methylation after TET gene inactivation. Furthermore, bivalent promoters with DNMT3B peaks in TKO hESCs showed greater methylation increase (TKO versus WT) and greater methylation decrease (QKO versus TKO) than bivalent promoters that lacked DNMT3B peaks in TKO hESCs and non-bivalent promoters with DNMT3B peaks in TKO hESCs (Fig. 8e ). Thus, DNMT3B binding correlates with more dynamic changes in DNA methylation at bivalent promoters, suggesting that at these promoters the TET and DNMT3B proteins function in a competitive manner.
Discussion
In mouse and human ESCs 40, 41 , the promoter regions of differentiation-associated genes are enriched for bivalent marks. Previous studies have focused on the establishment and maintenance of bivalent histone marks. However, it was unclear whether DNA methylation is also actively regulated at bivalent promoters and, if so, whether it has functional relevance for cell differentiation. Here we show that the TET proteins are critical for maintaining a hypomethylated state at bivalent promoters in hESCs. Although we focused on lineage regulators such as PAX6 and SOX10, bivalent promoters may also regulate signaling pathways during development that, along with regulation of enhancers and other regulatory regions, contribute to proper embryonic development and cellular differentiation. Notably, alteration of DNA methylation at bivalent promoters does not cause immediate changes in transcription in hESCs but nonetheless impairs hESC differentiation. We therefore propose to revise the predominant approach for studying epigenetic regulators, which focuses on epigenetic changes (including changes in DNA methylation) that have an immediate impact on gene expression, by expanding the analysis to additional epigenetic changes that do not immediately affect gene expression but may influence future cell behavior during embryonic development or adult stem/progenitor cell differentiation.
Previous studies have indicated that genomic regions marked by the H3K4me3 modification are refractory to de novo DNA methylation 42, 43 . TET gene deletion causes bivalent promoter hypermethylation without causing significant changes in H3K4me3 occupancy ( Supplementary Fig. 8f ). One possibility is that some of the effects associated with the H3K4me3 mark could be due to TET proteins, TET-dependent 5hmC, or TET-associated proteins, which may often co-occur with H3K4me3 44 . A second, non-mutually exclusive possibility is that de novo methyltransferases may be actively recruited to bivalent promoters in the absence of TET proteins, overcoming the repulsion by H3K4me3. In fact, it was recently shown that the Polycomb repressive complex 2 (PRC2) recruits DNMT3L, DNMT3A and DNMT3B to the bivalent promoters of genes involved in germ cell differentiation 45 .
It was also interesting that this aberrant hypermethylation at bivalent promoters, once established in TKO hESCs, is not adequately maintained by DNMT1. On the basis of the >99.7% overall fidelity of DNMT1 in preserving methylation 46 , DNMT1 would be expected to largely preserve the hypermethylation seen in TKO hESCs during the approximately six passages it takes to generate and expand QKO cells for analysis. Yet, we observed a global reduction in DNA methylation at bivalent promoters, including the PAX6 P0 promoter, in QKO cells, indicating that the hypermethylation phenotype requires continuous DNMT3B activity. This result also suggests that additional mechanisms, such as transient transcription 47 , Fig. 8 | DNMT3B regulates the methylation level at bivalent promoters. a, Average methylation at different genomic regions and bivalent promoters for WT, TKO and QKO hESCs by ERRBS; n = 2 independent experiments. Data are presented as means ± s.d. Statistical analysis was performed by one-way ANOVA: *P < 0.05, **P < 0.01. b, Percentage methylation in WT, TKO and QKO hESCs for active, initiated, bivalent and silent promoters. Error bars show the 10-90% confidence interval. The lower and upper limits of the box represent the first and third quartile, respectively, and the bar at the center of the box indicates the median. n = 2 independent experiments. Statistical analysis was performed by one-way ANOVA: **P < 0.01, ***P < 0.001, ****P < 0.0001. c, Top, overlap of bivalent promoters with hyper-DMRs (TKO versus WT) and hypo-DMRs (QKO versus TKO) at promoter regions. Bottom, overlap of non-bivalent promoters with hyper-DMRs (TKO versus WT) and hypo-DMRs (QKO versus TKO) at promoter regions. The odds ratio (OR) and P value for the comparison between bivalent and non-bivalent promoters are provided (Fisher's exact test). d, Overlap between bivalent promoters associated with hyper-DMRs (TKO versus WT) and hypo-DMRs (QKO versus TKO). e, Left, methylation changes (TKO -WT) for bivalent and non-bivalent promoters that either had (+ DNMT3B) or did not have (-DNMT3B) DNMT3B peaks in TKO hESCs. Right, methylation changes (QKO -TKO) for bivalent and nonbivalent promoters that either had (+ DNMT3B) or did not have (-DNMT3B) DNMT3B peaks in TKO hESCs. Error bars show the 10-90% confidence interval. The lower and upper limits of the box represent the first and third quartile, respectively, and the bar at the center of the box indicates the median. n = 2 independent experiments. Statistical analysis was performed by one-way ANOVA: ****P < 0.0001.
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NATurE GENETICS may inhibit DNMT1 activity at these loci, which may be an additional protective measure against hypermethylation of bivalent promoters even in TKO hESCs. Alternatively, although not necessarily in a mutually exclusive manner, DNMT3B may function as both a de novo and maintenance methyltransferase, as previously suggested 48, 49 . It must be noted, however, that the maintenance function of DNMT3A and DNMT3B has only been observed for limited genomic regions in mESCs, such as repetitive sequences 48, 49 , and inactivation of both DNMT3A and DNMT3B in hESCs only causes gradual DNA demethylation 46 .
Previous studies have shown that DNMT3A and DNMT3B have largely overlapping targets 46 , yet deletion of DNMT3B alone in TKO hESCs was sufficient to partially reverse bivalent promoter hypermethylation along with the associated neuroectoderm differentiation defect. DNMT3B may have stronger preference or activity, in comparison to DNMT3A, at bivalent promoters such as the PAX6 P0 promoter, and such loci have been identified previously in hESCs 46 . Perhaps more likely, the rescue by DNMT3B deletion alone could be due to the relatively low DNMT3A expression as compared to that of DNMT3B ( Supplementary Fig. 8a ) and the lack of compensatory increase in DNMT3A expression upon DNMT3B deletion ( Supplementary Fig. 8g ). Similarly, a recent paper found that inactivating either DNMT3A or DNMT3B in TET TKO mouse embryos was able to rescue the gastrulation phenotype 10 . It is possible that in other cell types DNMT3A, along with or instead of DNMT3B, may counteract the TET proteins to regulate DNA methylation 50, 51 .
Our work highlights the utility of locus-specific epigenome editing tools to directly probe the functional consequences of epigenetic changes and to distinguish direct, locus-specific effects from indirect effects 52 . The competitive balance between the TET proteins and de novo methyltransferases at bivalent promoters and other genomic loci could facilitate rapid changes in methylation state to either activate or silence transcription in a cell-lineage-and locus-specific manner. Further work could investigate the factors that influence whether the methylation state of a genomic region is dynamically regulated and, ultimately, how methylation states predict (in the context of cell differentiation) cell-type-specific transcriptional programs.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0002-y.
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F12 medium (Life Technologies, 12500-062), glucose (Sigma, G8270), sodium bicarbonate (Sigma, S5761), putrescine (Sigma, P5780), progesterone (Sigma, P8783), sodium selenite (Sigma, S5261), apo-transferrin (Sigma, T1147) and insulin (Sigma, I2643).
RNA-seq.
For RNA-seq, total RNA was isolated with the RNeasy Mini kit (Qiagen, 74136) from WT and TKO HUES8 hESCs (n = 2 cultures each). RNA samples were submitted to the MSKCC Integrated Genomics Core for library preparation and sequencing.
RNA-seq data were aligned to the hg19 reference genome using Bowtie 54 . Read counts were derived from the HTSeq.scripts.count module in HTSeq-0.6.0 with default parameters in a non-directional model 55 . Lists of differentially expressed genes were generated by DESeq2-1.4.5 in R 56 . Upregulated genes were defined by log(fold change) > 2 and P adj < 0.1 (n = 134). Downregulated genes were defined by log(fold change) < -2 and P adj < 0.1 (n = 233). 5hmC profiling. 5hmC-Seal was performed as previously described 22 . 40 μg of genomic DNA was sonicated into ~200-to 400-bp fragments using a Diagenode Bioruptor Sonicator. Sonicated DNA was then labeled with azide glucose in a 1-h reaction at 37 °C catalyzed by recombinant β-GT using UDP-6-N 3 -glucose as the sugar donor. The reactions were cleaned up using a Zymo DNA Clean & Concentrator kit (Zymo, D4003), and a biotin moiety was then added to the azide-labeled DNA via a copper-free click chemistry reaction with DBCO-S-S-PEG3-biotin in water at 37 °C for 1 h. Reactions were once again cleaned with the Zymo kit and then bound to MyOne Streptavidin C1 Dynabeads (Life Technologies, 65001) for 15 min at room temperature. Beads were washed five times with binding buffer (5 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1 M NaCl, 0.01% Tween-20). Bound DNA was eluted by reducing the disulfide in the biotin linker with 100 mM DTT for 2 h at room temperature with gentle rotation. Eluted DNA was cleaned on a Micro Bio-spin Column (Bio-Rad, 7326204) to remove DNA and then purified by the Zymo kit. Libraries were constructed from eluted DNA by end repair, A-tailing and adaptor ligation, followed by 4 cycles of PCR, size selection via agarose gel electrophoresis, 12 additional PCR cycles and a final size selection via agarose gel electrophoresis. Library quantity and quality were analyzed by Bioanalyzer before sequencing on an Illumina HiSeq 2500. Sequence alignment and peak identification were performed as previously described 22 . Peak calling was performed by macs14 1.4.2 with default parameters 57 .
WGBS and ERRBS.
For WGBS, genomic DNA was isolated from WT and TKO HUES8 hESCs. Genomic DNA was sheared using an E220 focused ultrasonicator (Covaris) into 250-to 350-bp fragments. After end repair and TruSeq adaptor (Illumina) ligation, DNA libraries were denatured and treated with bisulfite (Zymo Research, D5020) for 30 min at 65 °C. ssDNA was purified using silica gel columns and amplified using HiFi Uracil+ polymerase (Kapa Biosciences, KK2802). The amplified libraries were quantified and mixed equimolarly for sequencing on an Illumina HiSeq 2500 by the MSKCC Integrated Genomics core. One replicate each for WT and TKO HUES8 cells was submitted for sequencing.
For ERRBS, genomic DNA was isolated from WT, TKO and QKO HUES8 hESCs. Genomic DNA was submitted to the Weill Cornell Medical College Epigenomics core for ERRBS. Two independent replicates each for WT, TKO and QKO HUES8 cells were submitted for sequencing.
WGBS data were aligned to the bisulfite-converted hg19 reference genome using Bismark v0.13.0 58 . We extracted methylation status with the bismark_ methylation_extractor script in Bismark 58 . Only CpGs with at least three reads covering them were used for downstream analysis. The WCMC Computational Genomics core facility supported alignment and methylation extraction for ERRBS data 59 . DMRs were defined as regions containing at least five differentially methylated CpGs (DMCs; false discovery rate = 20%, chi-squared test) and whose total methylation difference was more than 10% 60 . For Fig. 1h and Supplementary  Fig. 3b ,c, hypermethylation was defined as a 5% increase in methylation to set a uniform cutoff for comparison between different promoters or cell lines. For Supplementary Fig. 3b ,c, hypomethylation was defined as a 5% decrease in methylation. For WGBS, only one replicate was used, but the use of five or more DMCs partially overcomes the statistical limitation of individual chi-squared tests based on an n = 1 sample, as the latter should be interpreted with caution in the absence of multiple measurements from independent samples. DMR calling was performed with RRBSeeqer with default parameters 60 . DMRs were annotated using ChIPseeqerAnnotate from the ChIPseeqer package 61 . Methylation of a specific region was calculated by averaging the methylation levels of all CpGs covered in that region.
Genomic regions for CpGs were defined according to the following definitions. CGIs were defined using annotations from RefSeq. CGI shores were defined as the regions encompassing 1 kb upstream and downstream of known CGIs. Non-CGIs were defined as regions at least 10 kb away from known CGIs. Promoters were defined as the regions encompassing 2 kb upstream and downstream of the TSS of RefSeq genes. The following characteristics were used to classify promoters as active, initiated, bivalent Methods hESC culture. HUES8 (NIHhESC-09-0021) and MEL-1 (NIHhESC-11-0139) hESCs were cultured on irradiated mouse embryonic fibroblast (iMEF) feeder layers in DMEM/F12 medium (Life Technologies, 12500-062) supplemented with 20% KnockOut Serum Replacement (Life Technologies, 10828028), 1 × MEM Non-Essential Amino Acids (Life Technologies, 11140050), 1 × GlutaMAX (Life Technologies, 35050079), 100 U/ml penicillin and 100 μg/ml streptomycin (Gemini, 15070063), 0.055 mM 2-mercaptoethanol (Life Technologies, 21985023) and 10 ng/ml recombinant human bFGF (EMD Millipore, GF003AF). Cells were incubated at 37 °C with 5% CO 2 , and medium was changed daily. Cultures were passaged at a 1:6 to 1:12 split ratio every 4-6 d using TrypLE (Life Technologies, 12563-029). 5 µM Rho-associated protein kinase (ROCK) inhibitor Y-27632 (Selleck Chemicals, S1049) was added into the culture medium when passaging or thawing cells. Cells are regularly confirmed to be mycoplasma free by the MSKCC Antibody & Bioresource Core Facility.
Generation of mutant lines. In vitro transcription of gRNAs. CRISPR gRNAs were designed to target the genomic sequences corresponding to the beginning of the catalytic domains for TET1, TET2 and TET3. For TET1 and TET3, the two gRNAs most efficient at producing indel mutations were used for the targeting experiments. For TET2, only one gRNA was found to be efficient at producing frameshift indel mutation. A CRISPR gRNA from a previous study was used to target the sequence encoding the C5 methyltransferase domain of DNMT3B 46 . The procedure to generate mutants has been previously described 53 . For each CRISPR gRNA, a 20-bp T7 promoter was added to the 20-bp gRNA target sequence (Supplementary Table 1 ) followed by an 80-bp constant gRNA backbone to form a 120-bp oligonucleotide. The T7-gRNA oligonucleotide was amplified by PCR, and T7-gRNA PCR products were used as templates for in vitro transcription using the MEGAshortscript T7 kit (Life Technologies, AM1354M). The resulting gRNAs were purified using the MEGAclear kit (Life Technologies, AM1908M), eluted in RNase-free water and stored at -80 °C until use.
Transfection of gRNAs or gRNA + single-stranded DNA. HUES8 and MEL-1 iCas9 hESCs 21 or HUES8 TKO hESCs were treated with ROCK inhibitor and doxycycline 1 d before transfection. For transfection, confluent cells were dissociated using TrypLE (Life Technologies, 12563-029), replated at a 1:6 ratio in iMEF-coated 24well plates and transfected in suspension with gRNAs or a mixture of gRNA and single-stranded DNA (ssDNA). A second transfection was performed 24 h later. Transfection was performed using Lipofectamine RNAiMAX (Life Technologies, 13778-150) following the manufacturer's guidelines. For each targeting, TET1, TET2, TET3 and DNMT3B gRNAs, each at a 10 nM final concentration, were used. For repair of the TET1 allele in TKO hESCs, gRNA and ssDNA (wild-type TET1 sequence) were transfected at a 10 nM and 20 nM concentration, respectively. Lipofectamine RNAiMAX and gRNA or gRNA + ssDNA were diluted separately in Opti-MEM (Life Technologies, 31985070) and then mixed together, incubated for 5 min and added dropwise to cultured hESCs.
Isolation, expansion and identification of mutant clones. Two days after the last gRNA transfection, hESCs were dissociated into single cells and replated at ~2,000 cells per 10-cm dish. Cells were allowed to grow until colonies from single cells became visible (~10 d). At this stage, single colonies were manually picked, mechanically disaggregated and replated individually into 96-well plates. Colonies were amplified and analyzed by Sanger sequencing at the three TET genes and DNMT3B for the presence of mutations. Clonal cell lines carrying the desired mutations or TKO hESCs in which one TET1 allele was repaired were amplified and frozen down. For all targeting experiments (TET genes, DNMT3B and HDR of TET1), we also isolated and froze down lines that had undergone the targeting procedure but whose genomic sequence was not changed. These lines were used as passage-matched controls for methylation analysis and differentiation. hESC neuroectoderm differentiation. 90% confluent hESC cultures were disaggregated using TrypLE (Life Technologies, 12563-029) for 5 min and washed using hESC medium. Cells were plated on dishes coated with Matrigel (BD, 354234) in hESC medium with ROCK inhibitor at a density of 180,000-200,000 cells/cm 2 . After 12 h, differentiation into neuroectoderm was initiated by switching to KSR medium with 10 μM of the TGF-β inhibitor SB431542 (Tocris, 161410) and 100 nM of the BMP inhibitor LDN193189 (Axonmedchem, 1509). On days 1 and 2 of differentiation, the medium was removed and fresh KSR medium with 10 μM SB431542 and 100 nM LDN193189 was added. Starting on day 4 of differentiation, an increasing amount of N2 medium was added to the KSR medium every 2 d while maintaining 10 μM SB431542 and 100 nM LDN193189. On day 4, a 3:1 mixture of KSR:N2 medium was added, on day 6 a 1:1 mixture of KSR:N2 medium was added, and on day 8 a 1:3 mixture of KSR:N2 medium was added. Cells were isolated for analysis on day 10 of differentiation. KSR medium contains Knockout DMEM (Life Technologies, 10829018), Knockout Serum Replacement (Life Technologies, 10828028), 1 × MEM Non-Essential Amino Acids (Life Technologies, 11140050), 1 × GlutaMAX (Life Technologies, 35050079) and 2-mercaptoethanol (Life Technologies, 21985023). N2 medium contains DMEM/ ChIP-seq. ChIP-seq was performed for TET1 (WT hESCs) and DNMT3B (WT and TKO hESCs). WT and TKO hESCs were cultured in standard hESC medium, as described above. Approximately 5 × 10 7 cells were fixed, washed and snap frozen according to the Cell Fixation protocol from Active Motif (see URLs). ChIP and DNA sequencing were performed by Active Motif.
ChIP-seq data were aligned to the hg19 reference genomes using bowtie-0.12.9 with default parameters except -n 2 and -best 55 . Peak calling and analysis of read density in peak regions were performed by macs14 1.4.2 with default parameters 57 . The technical success of ChIP-seq analysis was confirmed using standard quality control measures and determined the overlap between TET1 binding and the presence of 5hmC. We observed that 52.6% of 5hmC peaks associated with gene promoters overlapped TET1 peaks ( Supplementary  Fig. 5f ), similar to previous results obtained from TET1 ChIP-seq in mESCs 44, 62 . Approximately 75% of total TET1 peaks overlapped with total 5hmC peaks present in WT HUES8 hESCs; in contrast, only 25% of TET1 peaks overlapped with randomly generated 5hmC peaks ( Supplementary Fig. 4e ). Random peaks were generated with ChIPseeqerCreateRandomRegions in ChIPseeqer-2.1 with default parameters. The lack of a complete overlap between 5hmC and TET1 peaks could be due to a number of factors, including the following: 5hmC production by TET2 and TET3, rapid turnover of 5hmC and reduced binding of TET1 to 5hmC. Peaks from ChIP-seq were annotated using ChIPseeqerAnnotate from the ChIPseeqer package 61 .
ChIP-qPCR. Confluent hESCs from a 10-cm dish were used for two immunoprecipitations. ChIP was performed using the SimpleChIP Plus Enzymatic Chromatin IP kit (Cell Signaling Technology, 9003 S) according to the manufacturer's protocols. The antibodies used for ChIP were as follows: histone H3 (Cell Signaling Technology, 9003 S), IgG (Cell Signaling Technology, 9003 S), TET1 (Genetex, GTX627420), DNMT1 (Active Motif, 39204), DNMT3A (Abcam, ab2850) and DNMT3B (Novus Biologicals, NB100-56514). Primers for ChIP-qPCR are provided in Supplementary Table 3 . 5mC methylation analysis by MassARRAY. hESCs were disaggregated using TrypLE, and genomic DNA was extracted using the DNeasy Blood & Tissue kit (Qiagen, 69504) following the manufacturer's guidelines. MassARRAY EpiTYPER analysis was performed through the WCMC Epigenomics core. MassARRAY EpiTYPER analysis consisted of bisulfite treatment of genomic DNA followed by PCR for the specific region of analysis, base-specific cleavage differentiating between previously methylated and unmethylated DNA, and MALDI-TOF mass spectrometry 63 . Primer sequences used for MassARRAY 5mC methylation analysis are provided in Supplementary Table 4 . The genomic coordinates of regions assayed by MassARRAY are provided in Supplementary Table 5 .
Design and generation of the PAX6 overexpression lentivirus construct. To generate the PAX6 overexpression construct, PAX6 cDNA from day 10 of WT neuroectoderm differentiation was tagged with a 2A-GFP sequence and inserted into a lentiviral backbone. The 2A-GFP sequence was amplified from the OCT4-eGFP-PGK-Puro plasmid (Addgene, plasmid 31937) using primers containing BamHI (Forward) and AscI (Reverse) sites. The PCR product for PAX6 cDNA was cloned into the pENTR-dTOPO vector (Thermo Fisher Scientific, K240020). Digestion of the PAX6-pENTR-dTOPO vector and the 2A-GFP PCR product with BamHI and Asc1 was followed by ligation to form the PAX6-2A-GFP-pENTR-dTOPO vector. The PAX6-2A-GFP insert was then transferred into a doxycyclineinducible lentiviral backbone through an LR reaction. Primers used for cloning are listed in Supplementary Table 6 Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work we publish. This form is published with all life science papers and is intended to promote consistency and transparency in reporting. All life sciences submissions use this form; while some list items might not apply to an individual manuscript, all fields must be completed for clarity.
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Describe how sample size was determined. The molecular pathways in fertilized eggs from normal and obese mice were investigated in this study, so no sample size calculation was performed.
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Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced. All attempts at replication are successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In this study, mice were randomly divided into two diet groups, one group receiving a HFD and the other group received a ND, and then their zygotes were examined.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was done in most experiments (except DNA damage analysis) in this study. Fertilized eggs were examined, not a typical animal study.
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No eukaryotic cell lines were used in this study.
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Female ICR mice three-week of age were purchased from Charles River Laboratories China Inc. Four-week-old female C57BL/6J and 10-20 weeks male ICR mice were purchased from Charles RiverLaboratories China Inc. C57BL/6J-lep(ob/ob) mice were purchased from The Jackson Laboratories, Bar Harbor, US.
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